Energy expenditure during gait in patients with mucopolysaccharidosis

doi:10.1590/S1413-78522013000200009

. 2013 Mar;21(2):116-9.

doi: 10.1590/S1413-78522013000200009.

Energy expenditure during gait in patients with mucopolysaccharidosis

Marcos Almeida Matos¹, André Prado¹, Gustavo Schenkel¹, Rosa Barreto², Angelina Xavier Acosta²

Affiliations

¹ Bahia School of Medicine and Public Health , Santa Casa de Misericórdia da Bahia; Hospital Santa Isabel - Salvador, BA, Brazil.
² University Hospital Professor Edgar Santos; Faculdade de Medicina da Universidade Federal da Bahia - Salvador, BA, Brazil.

PMID: 24453654
PMCID: PMC3861965
DOI: 10.1590/S1413-78522013000200009

Energy expenditure during gait in patients with mucopolysaccharidosis

Marcos Almeida Matos et al. Acta Ortop Bras. 2013 Mar.

. 2013 Mar;21(2):116-9.

doi: 10.1590/S1413-78522013000200009.

Authors

Marcos Almeida Matos¹, André Prado¹, Gustavo Schenkel¹, Rosa Barreto², Angelina Xavier Acosta²

Affiliations

¹ Bahia School of Medicine and Public Health , Santa Casa de Misericórdia da Bahia; Hospital Santa Isabel - Salvador, BA, Brazil.
² University Hospital Professor Edgar Santos; Faculdade de Medicina da Universidade Federal da Bahia - Salvador, BA, Brazil.

PMID: 24453654
PMCID: PMC3861965
DOI: 10.1590/S1413-78522013000200009

Abstract

Objective: The aim of this study is to evaluate energy expenditure in gait by mucopolysaccharidosis affected patients by means of a simple and adequate to the clinical environment methodology.

Methods: A cross-sectional study was carried out comparing energy expenditure during gait in 19 patients suffering from mucopolysaccharidosis (MPS Group) with 19 asymptomatic control individuals (Control Group). Energy expenditure was measured in calories (cal) using a Polar telemetric watch (model FT7) during a 50 meter walk. Variables such as age, weight, height, body mass index (BMI), initial hart rate, final hart rate, and walking time, were recorded.

Results: MPS Group showed a mean energy expenditure during gait of 2.84 cal (±1,01), versus 1.42 cal (±0,51), 100% higher than the Control Group; MPS also presented increased initial hart rate (22% higher), final hart rate (13% higher) and walking time (13% higher).

Conclusions: Energy expenditure during gait in MPS patients was two times higher than control individuals; the methodology used showed to be a promising alternative, also adequate to the standard clinical environment. Level of Evidence III, Cross-sectional Comparative Study.

Keywords: Evaluation; Gait; Mucopolysaccharidosis I.

PubMed Disclaimer

Conflict of interest statement

All the authors declare that there is no potential conflict of interest referring to this article.

Cited by

Three-dimensional Evaluation of Gait: Kinetics, Kinematics, and Electromyographic in Patients with Mucopolysacharidosis Types IV and VI.
Rego FRQ, Oliveira HFV, Rolim Filho EL. Rego FRQ, et al. Rev Bras Ortop (Sao Paulo). 2024 Jul 22;59(5):e737-e744. doi: 10.1055/s-0044-1786200. eCollection 2024 Oct. Rev Bras Ortop (Sao Paulo). 2024. PMID: 39649053 Free PMC article.
Applying the functional independence measure to the assessment of patients with mucopolysaccharidosis.
Almeida Matos M, Silva Lopes P, Rodrigues Corsini A, Rodi J, Fong CT. Almeida Matos M, et al. Colomb Med (Cali). 2020 Sep 30;51(3):e213996. doi: 10.25100/cm.v51i3.3996. Colomb Med (Cali). 2020. PMID: 33402755 Free PMC article.
FUNCTIONAL INDEPENDENCE OF PEDIATRIC PATIENTS WITH MUCOPOLYSACCHARIDOSES.
Lopes PS, Serra DP, Matos MAA. Lopes PS, et al. Acta Ortop Bras. 2019 Jul-Aug;27(4):212-215. doi: 10.1590/1413-785220192704187274. Acta Ortop Bras. 2019. PMID: 31452622 Free PMC article.

References

1. Neufeld EF, Muenzer J. The mucoplysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 3421–3452.
1. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5–5. - PMC - PubMed
1. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267–277. - PMC - PubMed
1. Boyd R, Fatone S, Rodda J, Olesch C, Starr R, Cullis E, et al. High- or low- technology measurements of energy expenditure in clinical gait analysis? Dev Med Child Neurol. 1999;41(10):676–682. - PubMed
1. Fredrickson E, Ruff RL, Daly JJ. Physiological Cost Index as a proxy measure for the oxygen cost of gait in stroke patients. Neurorehabil Neural Repair. 2007;21(5):429–434. - PubMed

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Other Literature Sources
- scite Smart Citations

[1] Neufeld EF, Muenzer J. The mucoplysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 3421–3452.

[2] Neufeld EF, Muenzer J. The mucoplysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. pp. 3421–3452.

[3] Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5–5. - PMC - PubMed

[4] Valayannopoulos V, Nicely H, Harmatz P, Turbeville S. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5–5. - PMC - PubMed

[5] Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267–277. - PMC - PubMed

[6] Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267–277. - PMC - PubMed

[7] Boyd R, Fatone S, Rodda J, Olesch C, Starr R, Cullis E, et al. High- or low- technology measurements of energy expenditure in clinical gait analysis? Dev Med Child Neurol. 1999;41(10):676–682. - PubMed

[8] Boyd R, Fatone S, Rodda J, Olesch C, Starr R, Cullis E, et al. High- or low- technology measurements of energy expenditure in clinical gait analysis? Dev Med Child Neurol. 1999;41(10):676–682. - PubMed

[9] Fredrickson E, Ruff RL, Daly JJ. Physiological Cost Index as a proxy measure for the oxygen cost of gait in stroke patients. Neurorehabil Neural Repair. 2007;21(5):429–434. - PubMed

[10] Fredrickson E, Ruff RL, Daly JJ. Physiological Cost Index as a proxy measure for the oxygen cost of gait in stroke patients. Neurorehabil Neural Repair. 2007;21(5):429–434. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Energy expenditure during gait in patients with mucopolysaccharidosis

Affiliations

Energy expenditure during gait in patients with mucopolysaccharidosis

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources